Clinical Trial Update: Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma [Phase 1]

View source ↗

Summary

This document provides an update on a Phase 1 trial evaluating anti-GPC3 CAR T cells for recurrent or refractory lung squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Squamous Cell Carcinoma

Drugs mentioned

• Anti-GPC3 CAR T (CAR T-cell therapy targeting Glypican-3 (GPC3))

Snippet

Sponsor: CARsgen Therapeutics Co., Ltd. | Conditions: Lung Squamous Cell Carcinoma | Phase 1 | Status: UNKNOWN